Creative Medical Tech (CELZ) Soars 68% on Positive StemSpine Data

Trade CELZ Stock Your Capital Is At Risk
Ollie Martin
Updated: 23 Mar 2022

Key points:

  • Creative Medical Technology soars 68% on positive data from StemSpine two-year study
  • The study confirms the efficacy of the treatment in reducing chronic lower back pain
  • CEO exclaims the importance of bringing a non-surgical option to the market

A leader in today’s top daily gainers, Creative Medical Technology (NASDAQ: CELZ) skyrocketed around 68% this morning after investors reacted well to the company announcing positive long-term data surrounding a leading chronic back pain treatment; StemSpine. CELZ stock reached gains of over 80% before consolidating slightly lower. 


The company is known for working towards a regenerative approach to immunotherapy, urology, neurology, and orthopedics. A two-year study of StemSpine alludes to the significant efficacy of the treatment in reducing non-surgical chronic lower back pain.

Read Also: Best Healthcare Stocks To Buy Right Now

The treatment works by utilizing the patient’s own bone marrow aspirate for effective treatment of chronic lower back pain; a ground-breaking treatment in a critical area of medical treatment that is somewhat neglected. The study recorded no safety-related concerns over the two years, with the StemSpine procedure resulting in an impressive 87% efficacy rate in the concerned patients without any adverse effects. The long-term data is being prepared for peer review and eventually future orthopedic/sports medicine conferences. 

Offering an attractive non-surgical option for patients is an important step forward in the management of chronic pain. Timothy Warbington, President, and CEO of Creative Medical stated:

“The positive two-year data from our StemSpine® pilot study are very encouraging, and we are excited to engage with practitioners on commercialization…We believe StemSpine® represents an attractive non-surgical option for many of the millions of Americans who suffer from non-surgical chronic lower back pain.”

As with a lot of medical companies that announce new, potentially ground-breaking treatments; Creative Medical Technology is at risk of unnerving volatility moving forward. Today’s 68% price rise is unlikely to hold as momentum slows and profit-takers step it.

CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage . 68 % of retail investor accounts lose money when trading CFDs with this provider . You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money .